Published

Alzheimer's: EU authority rejects new antibody for treatment

Summary by Welt
High hopes were placed on the antibody preparation lecanemab for the treatment of Alzheimer's. The EU Medicines Agency is now speaking out against approving the drug — with clear reasons. What experts have to say about it.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.